Completes $200 million strategic financing with leading oncology-focused specialist investors "Testing for minimal residual disease has the potential to revolutionize oncology care and benefit ...
Acquisition establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market Forward-looking statements represent the Company's estimates only as of the date such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results